A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids
Clinical trial NCT02655224 · COMPLETED
Trial details
- NCT number
- NCT02655224
- Sponsor
- Takeda
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-03-26
- Primary completion
- 2017-05-16
- Enrollment
- 65
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.